Literature DB >> 23430832

Two Cases of Pulmonary Hypertension Associated with Type III Glycogen Storage Disease.

Teresa M Lee1, Erika S Berman-Rosenzweig, Alfred E Slonim, Wendy K Chung.   

Abstract

Glycogen storage diseases (GSDs) comprise a large, heterogeneous group of disorders characterized by abnormal glycogen deposition. Multiple cases in the literature have demonstrated an association between GSD type I and pulmonary arterial hypertension (PAH). We now also report on two patients with GSD type III and PAH, a novel association. The first patient was a 16-year-old girl of Nicaraguan descent with a history of hepatomegaly and growth retardation. Molecular testing identified a homozygous 17delAG mutation in AGL consistent with GSD type IIIb. At the age of 16, she was found to have PAH and was started on medical therapy. Two years later, she developed acute chest pain and died shortly thereafter. The second patient is a 13-year-old girl of Colombian descent homozygous for the c.3911dupA mutation consistent with GSD IIIa. An echocardiogram at age 2 showed left ventricular hypertrophy, which resolved following the institution of a high protein, moderate carbohydrate diet during the day and continuous gastric-tube feeding overnight. At the age of 12, she was found to have pulmonary hypertension. She was started on sildenafil, and her clinical status has shown marked improvement including normalization of her elevated transaminases. PAH may be a rare association in patients with GSD IIIa and IIIb and should be evaluated with screening echocardiograms for cardiac hypertrophy or if they present with symptoms of right-sided heart failure such as shortness of breath, chest pain, cyanosis, fatigue, dizziness, syncope, or edema. Early diagnosis of PAH is important as increasingly effective treatments are now available.

Entities:  

Year:  2011        PMID: 23430832      PMCID: PMC3509822          DOI: 10.1007/8904_2011_20

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  11 in total

1.  Pulmonary arterial hypertension in France: results from a national registry.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaici; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Gérald Simonneau
Journal:  Am J Respir Crit Care Med       Date:  2006-02-02       Impact factor: 21.405

Review 2.  Glycogen storage disease: clinical, biochemical, and molecular heterogeneity.

Authors:  Yoon S Shin
Journal:  Semin Pediatr Neurol       Date:  2006-06       Impact factor: 1.636

Review 3.  Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease.

Authors:  Monnipa Suesaowalak; John P Cleary; Anthony C Chang
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

4.  Type I glycogen storage disease with focal nodular hyperplasia of the liver and vasoconstrictive pulmonary hypertension.

Authors:  C J Pizzo
Journal:  Pediatrics       Date:  1980-02       Impact factor: 7.124

5.  Severe pulmonary arterial hypertension in type 1 glycogen storage disease.

Authors:  Marc Humbert; Philippe Labrune; Gérald Simonneau
Journal:  Eur J Pediatr       Date:  2002-07-31       Impact factor: 3.183

6.  Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis.

Authors:  M Humbert; P Labrune; O Sitbon; C Le Gall; J Callebert; P Hervé; D Samuel; R Machado; R Trembath; L Drouet; J M Launay; G Simonneau
Journal:  Eur Respir J       Date:  2002-07       Impact factor: 16.671

7.  Reversal of debrancher deficiency myopathy by the use of high-protein nutrition.

Authors:  A E Slonim; C Weisberg; P Benke; O B Evans; I M Burr
Journal:  Ann Neurol       Date:  1982-04       Impact factor: 10.422

Review 8.  Primary pulmonary hypertension.

Authors:  S P Gaine; L J Rubin
Journal:  Lancet       Date:  1998-08-29       Impact factor: 79.321

9.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

10.  Glycogen storage disease type III diagnosis and management guidelines.

Authors:  Priya S Kishnani; Stephanie L Austin; Pamela Arn; Deeksha S Bali; Anne Boney; Laura E Case; Wendy K Chung; Dev M Desai; Areeg El-Gharbawy; Ronald Haller; G Peter A Smit; Alastair D Smith; Lisa D Hobson-Webb; Stephanie Burns Wechsler; David A Weinstein; Michael S Watson
Journal:  Genet Med       Date:  2010-07       Impact factor: 8.822

View more
  3 in total

Review 1.  The genetic basis of pulmonary arterial hypertension.

Authors:  Lijiang Ma; Wendy K Chung
Journal:  Hum Genet       Date:  2014-01-21       Impact factor: 4.132

Review 2.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

3.  The biallelic novel pathogenic variants in AGL gene in a chinese patient with glycogen storage disease type III.

Authors:  Jing Wang; Yuping Yu; Chunquan Cai; Xiufang Zhi; Ying Zhang; Yu Zhao; Jianbo Shu
Journal:  BMC Pediatr       Date:  2022-05-16       Impact factor: 2.567

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.